These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27696389)

  • 1. Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience.
    Junus K; Aguilar M; Patel P; Irwin D; Yee S; Liu B; Bhuket T; Wong RJ
    Cancer; 2017 Feb; 123(4):650-656. PubMed ID: 27696389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
    Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
    World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
    Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
    Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
    Spinicci M; Emmi G; Dies L; Barilaro A; Vitiello G; Mencarini J; Cavallo A; Bartoloni A; Bartalesi F
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):756-760. PubMed ID: 29649073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B screening before rituximab therapy: a multicentre South Australian study of adherence.
    Hall SAL; Shaikh A; Teh K; Tantiongco M; Coghlan D; Karapetis CS; Chinnaratha MA; Woodman R; Muller KR; Wigg AJ
    Intern Med J; 2018 Aug; 48(8):936-943. PubMed ID: 29345413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
    Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
    Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Tien YC; Yen HH; Chiu YM
    Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
    Mozessohn L; Chan KK; Feld JJ; Hicks LK
    J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of rituximab-induced hepatitis B flare after antiviral discontinuation in rheumatic patients with chronic hepatitis B virus.
    Lan TY; Chang TW; Tseng TC; Lee TJ; Kao JH; Cheng CF; Huang SC; Shen CY; Lu CH; Yang HC; Li KJ; Hsieh SC
    Clin Exp Rheumatol; 2024 Sep; 42(9):1830-1837. PubMed ID: 38855955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving testing for hepatitis B before treatment with rituximab.
    Dyson JK; Jopson L; Ng S; Lowery M; Harwood J; Waugh S; Valappil M; McPherson S
    Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1172-8. PubMed ID: 27388147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B Virus Screening and Real Life Data in Patients with Solid Tumor Receiving Chemotherapy.
    Fidan S; Fidan E; Alandağ C; Erkut M; Cosar AM
    Arch Iran Med; 2020 Dec; 23(12):835-841. PubMed ID: 33356341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
    Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
    Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.